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Background. Neuroblastomas are characterized by chromosomal alterations with biological and clinical significance. We
analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity
(LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array. Findings. Multiple
areas of LOH and copy number gain were seen. The most commonly observed area of LOH was on chromosome arm 11q (15/22
samples; 68%). Chromosome 11q LOH was highly associated with occurrence of chromosome 3p LOH: 9 of the 15 samples with
11q LOH had concomitant 3p LOH (P = 0.016). Chromosome 1p LOH was seen in one-third of cases. LOH events on
chromosomes 11q and 1p were generally accompanied by copy number loss, indicating hemizygous deletion within these
regions. The one exception was on chromosome 11p, where LOH in all four cases was accompanied by normal copy number or
diploidy, implying uniparental disomy. Gain of copy number was most frequently observed on chromosome arm 17q (21/22
samples; 95%) and was associated with allelic imbalance in six samples. Amplification of MYCN was also noted, and also
amplification of a second gene, ALK, in a single case. Conclusions. This analysis demonstrates the power of SNP arrays for
high-resolution determination of LOH and DNA copy number change in neuroblastoma, a tumor in which specific allelic
changes drive clinical outcome and selection of therapy.
Citation: George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, et al (2007) Genome-Wide Analysis of Neuroblastomas using High-Density Single
Nucleotide Polymorphism Arrays. PLoS ONE 2(2): e255. doi:10.1371/journal.pone.0000255
INTRODUCTION
Neuroblastoma, like most human cancers, is characterized by
genomic instability, manifested at the chromosomal level as allelic
gain, loss, or rearrangement. These aberrations frequently are
associated with a particular disease phenotype, such as widespread
metastasis or early relapse, and are therefore clinically important.
Allelic imbalance in solid tumors can be detected by a variety of
methods, including sequence-specific hybridization of tumor cell
DNA at polymorphic loci across the human genome. Single
nucleotide polymorphisms (SNPs) provide a high-density method
for large-scale analyses of polymorphic markers. SNP arrays
provide a feasible means of conducting high-throughput, genome-
wide screens for allelic imbalance [1]. SNP array analysis enables
detection of genotypic alterations in the tumors of individual
patients and, in principle, identification of new areas with common
allelic imbalance that could harbor potential tumor suppressors.
Additionally, this method allows for simultaneous measurement
of DNA copy number [2]. SNP array analysis shows high
concordance with microsatellite methods, but allows detection of
smaller regions of LOH that maybe missed by microsatellite
mapping [3]. In addition, because LOH can occur without change
in DNA copy number, SNP arrays offer more potential than
comparative genomic hybridization in detecting such events. This
type of analysis has been used successfully to assess different
cancers [4–6].
Studies of neuroblastoma cells consistently identify LOH at
several chromosomal regions, some of which correlate with a poor
outcome, but tumor suppressor genes in these regions remain to be
identified. An example is the deletion of chromosome band 1p36,
which is strongly correlated with MYCN gene amplification, a very
poor prognostic marker in neuroblastoma [7,8], and which by
itself is also commonly associated with an advanced disease stage
and a poor outcome [9]. Chromosome band 11q23 LOH is
inversely related to MYCN amplification but also reliably identifies
patients at high risk for disease relapse [10]. Additionally,
unbalanced gain of chromosome 17q is associated with high-risk
disease features, such as advanced disease stage and age at
diagnosis, MYCN amplification, and 1p36 LOH, and a decreased
survival probability [11]. Thus, the available data clearly indicate
that DNA copy number aberrations are significant predictors of
disease phenotype and clinical behavior in neuroblastoma,
including likelihood of response to chemotherapy and/or eventual
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disease relapse. A chip-based method for whole-genome evalua-
tion of DNA alterations has the potential to streamline gene
discovery efforts and provide genomic signatures that may be
useful in predicting prognosis.
RESULTS
Characteristics of the patients and tumor samples
Age at diagnosis ranged from 6.5 months to 11.6 years, with
a median of 3.3 years. Majority (19/22 or 86.4%) of patients were
over a year old. All but one patient had metastatic disease at
diagnosis. MYCN amplification occurred in 5 tumors (22.7%) and
hyperdiploid DNA content in 15/22 (68.2%) tumors. Majority
(20/22) of the tumors had unfavorable Shimada histology. All 22
patients met the Children’s Oncology Group (COG) criteria for
having high-risk disease [12].
SNP array analysis
The average genotype call rates for tumor and normal samples were
93.763.7% (range: 82.4–98.5%) and 96.164.0% (range: 85.4–
99.0%), respectively. On average, 29.3% of the SNP loci were
informative (heterozygous in normal samples and all SNP calls
made in tumor samples except No call), with a range of 20.6–35.3%.
All samples assayed showed DNA copy number aberrations and
LOH (Figure 1). The median percentage of the genome with copy
number alterations in our sample set was 8.4% (range: 0.6–15.1%).
Detection of LOH
Six main regions of LOH were identified in this analysis (Table 1).
The most frequent region, present in 15 of 22 tumor samples
(68%; Figure 2), was on chromosome arm 11q. All 15 cases
showed large regions of LOH with retention of heterozygosity of
portions of 11p and 11q in all but one sample which demonstrated
whole chromosome 11 LOH (#427). A total of 6/14 cases (43%)
with 11q copy number loss showed a concomitant gain in copy
number on 11p. LOH of chromosome 3p was found in 45% of
cases (Table 1). Chromosome arm 11q and 3p LOH tended to
occur together: 9 of 15 cases with 11q deletion also had loss of 3p
(P= 0.016) (Figure 3). Only one case with 3p LOH lacked an
associated 11q LOH. Other regions of the genome that showed
appreciable LOH were 1p and 4p, which were detected in
approximately 32% and 27% of cases, respectively (Table 1).
LOH of chromosome 11p was also observed in 4 samples, and
chromosome 14q LOH observed in 2 samples (Figure 2).
Mechanisms of LOH
Almost all of the regions of LOH resulted from copy number loss.
In the case of chromosome 11q LOH, all 14 samples with apparent
chromosome 11 breakpoints showed copy number reduction of
the region of LOH, while the one sample with whole chromosome
11 LOH maintained two allelic copies of the entire chromosome
(Figure 2). Copy number loss accompanied LOH of chromosomes
3p, 1p, 4p and 14q. The 4 samples with chromosome 11p LOH,
however, had diploid copy numbers. In addition, in 6 tumors with
chromosome 17q LOH, there was a gain in copy number. In one
case (#427) an apparent copy-number reduction at chromosome
3p was not associated with LOH (Figure 3).
Although no homozygous deletions were unequivocally identi-
fied in this dataset, there was a potential homozygous deletion,
defined as an inferred copy number of ,0.3 in at least 2 consecu-
tive SNPs. The flanking SNPs define a 124 kb area at 10q26.2, to
which no known genes have been mapped.
Figure 1. Frequency of chromosomal aberrations. Fraction of samples with copy number .2.8 (red bars above baseline), copy number ,1.2 (grey
bars below baseline), and LOH (blue bars below baseline). SNPs are mapped according to their chromosomal position, from chromosome 1 on the
left to chromosome X on the right. (Copy number alterations for chromosome X in samples derived from males were counted if copy number was
.1.4 or ,0.6.)
doi:10.1371/journal.pone.0000255.g001
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Detection of copy number gain
Six chromosomal regions showed frequent gains of copy number
(Table 1; Fig. 1). The most common of these was chromosome
arm 17q in 21 of the samples (Figure 4). Each of these 21 samples
had 3 to 4 copies of 17q; 16 had an unbalanced gain of 17q
without a gain of 17p. Of the 21 tumors with a gain of 17q, 6 also
showed LOH on 17q (Figure 4).
A gain of chromosome 1q was found in 55% of the tumors,
while gain of chromosome arm 2p, the site of theMYCN oncogene,
was detected in 50% of the cases. Other notable findings were
whole chromosome 7 gain in 10 samples (45%), gain of whole
chromosome 18 in 5 samples, and isolated chromosome 18q gain
in 6 samples.
Regions of chromosomal amplification
High-level gene amplification events were less frequent than LOH
or copy number gains. MYCN amplification was seen in 3 cases on
10K SNP array analysis. However, 10K array analysis did not
detect MYCN amplification in 2 samples that showed multiple
copies by FISH. These two samples were re-analyzed using the
higher density 250K SNP array and clearly showed MYCN
amplification. A second area of amplification was found in one
tumor at chromosome 2p23, the site of the anaplastic lymphoma
kinase (ALK) gene on the 10K array. Amplification was observed in
three consecutive SNPs (20 copies of each SNP) encompassing the
ALK gene (Figure 5). Although bothMYCN and ALK are located on
chromosome 2, at 2p24.1, and 2p23.2 respectively, there were
more than 21 unamplified SNPs between the two genes.
Deletion mapping
Overlapping areas of deletion defined the smallest regions of
overlap (SRO). All 11q deletions extended to the telomere; the
smallest covered 29.8 Mb from 11q22.3-tel. There were two
common regions of deletion on 3p: a 28.4 Mb region within
3p26.3-24.1 and a 12.6 Mb region within 3p21.31-14.3.
Comparison with other methods of detecting allelic
imbalance
10K SNP array analysis did not detect MYCN amplification in 2
samples that showed multiple copies by FISH (concordant results
in 3/5 samples). However, MYCN amplification was clearly seen
when these two tumors were analyzed by the higher density 250K
StyI array (Affymetrix Inc.). Non-amplified MYCN was confirmed
by both FISH and 10K SNP array analysis in 17 samples. One
sample scored as LOH on chromosome 1p by PCR genotyping
but did not display LOH by SNP. Although all expected samples
with 11q LOH were detected by both methods, 4 samples
previously determined to have whole chromosome 11 LOH by
Figure 2. LOH and copy number changes on chromosome 11. SNP array analysis of neuroblastoma tumor samples and matched constitutional DNA
showing LOH on the left and copy number on the right of the chromosome 11 ideogram. For each sample, chromosome 11 is depicted as a vertical
bar in both the LOH and copy number panels. Blue areas represent regions of LOH, while yellow denotes retention of heterozygosity. Copy number is
marked by shades of red, with #1 copy in light red and$3 copies in dark red (see scale at the bottom of the panel). Both chromosome 11q and 11p
LOH, as well as gain of 11p, are shown.
doi:10.1371/journal.pone.0000255.g002
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microsatellite mapping actually had areas of chromosome 11
without LOH on SNP array analysis. The SNP array analysis was
concordant in 13/16 cases of unbalanced 17q gain by PCR.
Associations between allelic imbalances and MYCN
amplification
Although the number of samples was small, chromosome arm 1p
LOH was significantly correlated with MYCN amplification
(P = 0.0002). On the other hand, 11q LOH was significantly
associated with non-amplified MYCN (P = 0.0008), as was whole
chromosome 7 gain (P= 0.04).
DISCUSSION
This study represents the application of SNP arrays in the genome-
wide analysis of LOH and DNA copy number change in
neuroblastoma. We have previously reported a method of
assessing region-specific LOH in neuroblastoma using a SNP-
based tag-array platform [13]. In this assay, informative SNPs
from nine known regions of LOH in neuroblastoma were
identified and used in designing a customizable platform of 500
SNPs. This array reliably detected LOH in 6 or more genomic
regions, obviated the requirement for matched constitutional
DNA, and would be very useful as a neuroblastoma-specific chip
to achieve prognostication, but would fail to uncover novel areas
of LOH and copy number gain. The Affymetrix 10K array we
used in this study permits the simultaneous genotyping of 11,560
SNPs spaced throughout the human genome at a median inter-
marker distance of 100 kb. SNP array analysis identified multiple
known areas of allelic imbalance in neuroblastomas, such as LOH
of chromosomes 11q, 3p, 1p, and 4p. In addition, novel findings
were the uniparental disomy that accompanied chromosome 11p
LOH and the finding of allelic imbalance with chromosome 17q
gain. Amplification of ALK, a gene with transforming activity in
anaplastic large cell lymphoma was also seen.
Deletions of 11q have been noted in approximately 35% to 45%
of neuroblastomas using microsatellite markers, CGH, and FISH
and are consistently seen in MYCN non-amplified tumors
[10,14,15]. None of the tumors in our study with 11q LOH had
MYCN amplification [10]. Moreover, 9 of 10 tumors with 3p LOH
had concomitant 11q LOH, as previously reported [15]. The
nonrandom association of 3p LOH with 11q LOH in neuroblas-
toma likely signifies losses of tumor suppressor genes on these
chromosome arms and may represent a synergistic alternative
oncogenic pathway in high-risk tumors lacking MYCN amplifica-
tion. Chromosome 1p LOH was documented in 32% of samples
in this study and was associated with MYCN amplification, as
described previously [9,10]. The deletions of 1p defined an SRO
of 7.8 Mb within 1p36.32-36.22, which includes the common
region of deletion defined by White et al [16].
SNP array analysis simultaneously detects LOH and copy
number changes and therefore can be used to elucidate the
mechanisms underlying LOH. In this analysis, LOH was
accompanied by copy number loss, normal copy number, and
Table 1. Common regions of LOH in high-risk neuroblastoma and corresponding copy number change (A), and areas of copy
number gain (B) identified by 10K SNP array analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A. Areas of LOH
Chromosomal Region
Smallest Region of
Overlap (Mb) N (%)
Corresponding Copy Number
Change (N, %) Suggested Mechanism
1p ter-38.9 7 (32%) Reduction (7, 100%) Hemizygous deletion
3p ter-44.2 10 (45%) Reduction (10, 100%) Hemizygous deletion
4p ter-23.2 6 (27%) Reduction (6, 100%) Hemizygous deletion
11q 105.6-134.5 15 (68%) Reduction (14, 93%) Hemizygous deletion
No change (1, 7%) Copy neutral events
11p ter-15.2 4 (18%) No change (4, 100%) Copy neutral events
14q 98.9-106.3 2 (9%) Reduction (2, 100%) Hemizygous deletion
B. Areas of Copy Number Gain
Chromosomal Region Smallest Region of Overlap (Mb) Tumors with Copy Number Gain (%)
1q 183.65–197.3 12 (55%)
222.05–228.6
2p 7–29.6 11 (50%)
7 15 (68%)
7p only ter–34.75 2 (9%)
7q only 107.02-ter 3 (14%)
Whole chromosome 7 10 (45%)
11p 16.1–26.0 6 (27%)
17q 21 (95%)
17q only 44.83-ter 16 (73%)
Whole chromosome 17 5 (23%)
18q 11 (50%)
18q only 41.76-ter 6 (27%)
Whole chromosome 18 5 (23%)
doi:10.1371/journal.pone.0000255.t001..
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copy number gain. Copy number loss accounted for most of the
regions of LOH and was found on chromosomes 11q, 3p, 1p, and
4p, in which genes on the retained alleles are thought to be
haploinsufficient or inactivated by intrachromosomal deletions,
mutations, or epigenetic phenomena.
LOH with a normal copy number was documented in all 4 of
the tumors with LOH on chromosome 11p. Such LOH without
accompanying copy number reduction, termed ‘‘copy-neutral’’
events have been reported in rhabdomyosarcoma [17], breast
cancer [18], and acute myeloid leukemia [19], and are thought to
be due to uniparental disomy, which result in the loss of one allele
and duplication of the retained allele. The fact that in 3 tumors
(#1204, 205, and 1092) the regions of 11p LOH extended to the
telomere suggests that this phenomenon is likely due to somatic
recombination. In tumor #427, entire chromosome 11 LOH is
seen, suggesting either a somatic recombination event close to the
centromere or a nondisjunction event with subsequent chromo-
somal duplication. This may result in gain of function of the genes
in this region, as for example, IGF2, which is known to induce
neuroblastoma cell proliferation [20]. Alternatively, the targeted
gene within this region on the duplicated allele may also contain
inactivating mutations or be suppressed by epigenetic mechanisms,
resulting in loss of function. Further studies are required to
determine which gene or genes are mutated and how the
mutations that led to their inactivation were selected for in the
first place.
We also observed LOH accompanied by an increase in copy
number on chromosome 17q. The loss of one allele followed by
a gain of the remaining allele would suggest the need to eliminate
the wild-type function of an activated oncogene. This phenom-
enon has been suggested previously in osteosarcomas, where LOH
was accompanied by a significant increase in copy number
[21]. Alternatively, copy number gain and the resulting allelic
imbalance may result in a false reading of LOH by the genotyping
algorithm [22]. Indeed, all three of our samples with MYCN
amplification on chromosome 2p24 appeared to have LOH at that
locus. Further studies will be needed to determine whether
chromosome 17q LOH in fact accompanies 17q gain in some
cases of neuroblastoma or whether this phenomenon is merely an
indication of allelic imbalance.
The association of gain of chromosome arm 11p with 11q loss was
seen in this analysis and has been reported in up to 55% of
neuroblastomas with 11q loss [23], suggesting cooperation between
tumor suppressors and oncogenes within these regions. Chromo-
some 17q gain was observed in all but 1 of the 22 (95%) tumors, and
thus was the most prevalent abnormality in our series [11,24]. Gain
of either the entire chromosome 7 or its long arm has been detected
in 40% of neuroblastomas by CGH [23]; in our study, 7q gain was
documented in 10/22 (45%) of tumors. In addition, chromosome 7q
gain has been significantly correlated with lack of MYCN
amplification, which was also the case in our series. Chromosome
7q gain has also been shown to occur through an unbalanced t(3;7)
Figure 3. LOH and copy number changes on chromosomes 11, 3, 4, 1, 17, and 7. Global view of common areas of LOH (left) and copy number change
(right) in 22 primary neuroblastomas. Each sample is depicted as a series of vertical bars in both the LOH and copy number panels. Blue areas
represent regions of LOH, while yellow denotes retention of heterozygosity. Copy number is marked by shades of red, with #1 copy in light red and
$3 copies in dark red (see scale at the bottom of the panel).
doi:10.1371/journal.pone.0000255.g003
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translocation with loss of 3p material [23]. In our series, 50% (7/14)
of tumor samples with 7q gain had concomitant loss of 3p, suggesting
synergistic tumor suppressor pathways.
We identified another area of amplification in our series, at
chromosome 2p23, the locus of the ALK gene [25]. ALK encodes
a tyrosine kinase receptor and was first identified as a component
of the NPM-ALK fusion gene in anaplastic large cell lymphoma. It
was shown to be constitutively activated by amplification at the
ALK locus in neuroblastoma cell lines [26], and suppression of
activated ALK in such cells induced apoptotic changes through
reduction in the phosphorylation of ShcC, a Src homology 2
domain-containing adaptor molecule involved in signaling
through the MAP kinase pathway. Although ALK is commonly
expressed in the cytoplasm of neuroblastoma cells, its amplification
has so far been demonstrated in only 1 of 85 tumor samples [27].
Amplification is correlated with expression. Although the tumor
sample with ALK amplification was known to harbor MYCN
amplification by FISH, MYCN amplification was not detected on
the 10K array due to the small MYCN amplicon size. When this
same sample was analyzed on a 250K array, MYCN amplification
was noted. On this latter array there were several intervening
SNPs between the MYCN and ALK genes that did not show
amplification, however this does not rule out ALK coamplification
with MYCN, as discontinuous regions of amplification may have
occurred. Nevertheless, the finding of ALK amplification in
neuroblastoma may provide a novel therapeutic target that could
be tested using available ALK inhibitor compounds.
SNP arrays have many advantages over more conventional
methods of cancer genome analysis in terms of efficiency, precision
and minimal DNA requirements, and may well become the
dominant technology for performing genome-wide tumor cell
LOH and copy number measurements. This application seems
especially relevant to large studies such as those of the Children’s
Oncology Group, in which treatment for neuroblastoma patients
is already based on genetic abnormalities and further stratifications
are planned based on 1p and 11q LOH [10]. Although the use of
high-density SNP arrays to provide clinically relevant information
has great appeal, this strategy must first be validated using newer
generation SNP arrays containing probes for more SNP markers
with higher informative rates. Ultimately, the results of cancer
genome-wide allelotyping by SNP array analysis may predict
responses to specific therapies, allowing more efficient modifica-
tion of regimens for individual patients.
METHODS
Patients and tumor samples
Samples were identified from the Children’s Oncology Group
(COG) Neuroblastoma Nucleic Acids Bank with the only inclusion
criteria being 1) availability of matched constitutional DNA from
Figure 4. Copy number and LOH analysis of chromosome 17. SNP array analysis of neuroblastoma tumor samples and matched constitutional DNA
showing LOH on the left and copy number on the right of the chromosome 17 ideogram. For each sample, chromosome 17 is depicted as a vertical
bar in both the LOH and copy number panels. Blue areas represent regions of LOH, while yellow denotes retention of heterozygosity. Copy number is
marked by shades of red, with#1 copy in light red and$3 copies in dark red (see scale at the bottom of the panel). This figure depicts copy number
gain of chromosome 17q in 21 out of 22 samples.
doi:10.1371/journal.pone.0000255.g004
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peripheral blood mononuclear cells; 2) samples obtained at
original diagnosis and immediately snap frozen; and 3) a tumor
cell content of more than 90% based on differential count, clonal
hyperdiploid percentage in some tumors, and direct examination
of H&E-stained tumors in a subset of cases. Patients were staged
according to the International Neuroblastoma Staging System
[28] and histology was analyzed by the Shimada Pathology
Classification [29]. MYCN gene amplification and DNA ploidy
were determined as previously described [30,31]. LOH and
chromosome gain status were determined on chromosome arms
1p, 3p, 11q, and 17q using conventional microsatellite markers as
previously described [10]. This project received joint approval
from the Institutional Review Boards of the Dana-Farber Cancer
Institute and the Children’s Hospital of Philadelphia.
Preparation of DNA target and SNP genotyping
The Affymetrix 10K SNP array was used in all initial experiments
and the 250K array in subsequent ones, according to the methods
described by the manufacturer. Briefly, 250 ng of tumor and
control DNA were digested with the appropriate restriction
enzyme (Xba1 for the 10K array and Sty1 for the 250K array) in
parallel reactions, and ligated to a universal adaptor sequence. For
each sample, the ligated DNA was PCR amplified under recom-
mended conditions, using primers complementary to the universal
adapters. The PCR products were then fragmented and end-
labeled with biotinylated ddATP using terminal deoxynucleotidyl
transferase. The labeled DNA was then hybridized to the 10K
SNP chips, washed, incubated with streptavidin, and stained with
Figure 5. Amplifications on chromosome 2p. (A) SNP copy number analysis of a portion of chromosome arm 2p demonstrating amplification
(represented by the darker red SNPs) at the MYCN gene locus (2p24.3) in three tumor samples and at the ALK gene locus (2p23.2) in one sample. (B)
Individual SNP copy number assessment of the SNPs surrounding the ALK locus. The blue curve in the graph on the right indicates the degree of
amplification of each SNP from 0 on the left to 40 on the right. The red vertical line indicates a copy number of 2. (C) FISH of neuroblastoma with the
MYCN probe showing multiple copies ofMYCN (left panel), and FISH of the same tumor using the ALK break apart probe showing amplification of ALK
(right panel).
doi:10.1371/journal.pone.0000255.g005
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biotinylated antistreptavidin antibody and a streptavidin R-
phycoerythrin conjugate. The chips were scanned with an HP
scanner (Hewlett-Packard, Palo Alto, CA) according to the
manufacturer’s recommendations. Affymetrix genotyping software
(Affymetrix GeneChip 5.0) was used to examine the SNP
hybridization patterns and to make SNP calls of all loci in each
of the tumor samples and their corresponding matched controls.
Analysis of LOH
The resulting data were analyzed with the dChip software package
[32], which is freely available at www.dchip.org. At each locus, 1
of 5 LOH calls was assigned by the dChip algorithm in a pair of
normal and tumor cells, according to the following rules: allelic
imbalance or LOH (AB in normal, A or B in tumor; blue);
retention of heterozygosity (AB in both normal and tumor;
yellow,); non-informative (A or B in normal, gray); no call (SNP
No Call in normal or tumor sample, white), or conflict (A or B in
normal and AB in tumor, red) (Fig. 2). A ‘‘region of LOH’’ was
assigned when there were at least 2 consecutive SNPs showing
LOH. The overall call rate was calculated as the number of SNPs
assigned A, B, or AB (all SNP calls except No call) divided by the
total number of SNPs in the array.
Measurement of DNA copy number change
Copy number change was measured based on comparing the
hybridization intensity between normal and tumor samples using
the dChip software, with a sliding window of 3 SNPs as previously
described [2]. Copy number gain was defined as between 2.8 and
5 copies (alleles). Amplification was defined as an inferred copy
number of greater than 5 in 3 consecutive SNPs. Copy number
loss was defined as less than 1.2 copies. Homozygous loss was
defined as an inferred copy number of ,0.3 in at least 2
consecutive SNPs.
Comparison with other methods of detecting allelic
imbalance
Results of the SNP arrays were compared with those of
conventional methods of detecting genomic aberrations in cancer
cells, including fluorescence in situ hybridization (FISH) for MYCN
amplification as described previously [30], microsatellite genotyp-
ing for LOH at 1p36 and 11q23 [10], and quantitative real-time
PCR for unbalanced 17q gain [33].
Statistical analysis
Tests of association between chromosomal abnormalities and
MYCN amplification were performed using a two-sided Fisher’s
Exact test.
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